Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes
Andrew F. Ziolkowski, … , Christopher R. Parish, Charmaine J. Simeonovic
Andrew F. Ziolkowski, … , Christopher R. Parish, Charmaine J. Simeonovic
Published December 19, 2011
Citation Information: J Clin Invest. 2012;122(1):132-141. https://doi.org/10.1172/JCI46177.
View: Text | PDF
Research Article Metabolism

Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes

  • Text
  • PDF
Abstract

The autoimmune type 1 diabetes (T1D) that arises spontaneously in NOD mice is considered to be a model of T1D in humans. It is characterized by the invasion of pancreatic islets by mononuclear cells (MNCs), which ultimately leads to destruction of insulin-producing β cells. Although T cell dependent, the molecular mechanisms triggering β cell death have not been fully elucidated. Here, we report that a glycosaminoglycan, heparan sulfate (HS), is expressed at extraordinarily high levels within mouse islets and is essential for β cell survival. In vitro, β cells rapidly lost their HS and died. β Cell death was prevented by HS replacement, a treatment that also rendered the β cells resistant to damage from ROS. In vivo, autoimmune destruction of islets in NOD mice was associated with production of catalytically active heparanase, an HS-degrading enzyme, by islet-infiltrating MNCs and loss of islet HS. Furthermore, in vivo treatment with the heparanase inhibitor PI-88 preserved intraislet HS and protected NOD mice from T1D. Our results identified HS as a critical molecular requirement for islet β cell survival and HS degradation as a mechanism for β cell destruction. Our findings suggest that preservation of islet HS could be a therapeutic strategy for preventing T1D.

Authors

Andrew F. Ziolkowski, Sarah K. Popp, Craig Freeman, Christopher R. Parish, Charmaine J. Simeonovic

×

Figure 4

Inhibition of heparanase activity in vivo protects NOD mice from T1D and destructive immunity.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of heparanase activity in vivo protects NOD mice from T1D and...
(A) NOD/Lt female mice (10.5–11 weeks) were injected daily i.p. with 10 mg/kg PI-88 (black; n = 23 per group) or saline (white; n = 25 per group). PI-88 treatment delayed the onset of diabetes by 70 days and reduced the incidence of diabetes to 30% compared with 62% in control mice. #P = 0.0039, *P = 0.0415 vs. saline. (B) Pancreases from nondiabetic PI-88– (black; n = 4 per group) or saline-treated (white; n = 3 per group) NOD/Lt mice at 253 days of age (from A) were analyzed histologically to assess the level of insulitis. PI-88 treatment significantly increased the percentage of islets lacking insulitis (normal) and significantly decreased the percentage of islets with DI, with a noticeable reduction also observed in completely destroyed (CD) islets. Results are mean ± SEM. *P = 0.0026; **P = 0.0244. (C) Additional serial pancreas sections from B were alternately stained with H&E and Alcian blue. PI-88 treatment preserved islet-associated HS in the presence of DI, compared with control islets from saline-treated mice, in which intraislet HS was severely disrupted. Scale bars: 100 μm. (D) Alcian blue staining intensity was significantly stronger in islets with DI from PI-88–treated mice than from control saline-treated mice from B (P = 0.0009), as quantified by Image J with Color Deconvolution plugin. Results are mean ± SD.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts